Skip Navigation



NDT Advance Access published online on June 14, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh941
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/9/1880    most recent
gfh941v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kalantar-Zadeh, K.
Right arrow Articles by Greenland, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalantar-Zadeh, K.
Right arrow Articles by Greenland, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received March 5, 2005
Accepted May 11, 2005

Original Articles

Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction

Kamyar Kalantar-Zadeh 1*, Ryan D. Kilpatrick 2, Noriko Kuwae 1, Charles J. McAllister 3, Harry Alcorn Jr 4, Joel D. Kopple 2, and Sander Greenland 5

1 Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, and David Geffen School of Medicine at UCLA, Torrance, CA 90502, USA
2 Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, and David Geffen School of Medicine at UCLA, Torrance, CA 90502, USA; School of Public Health, University of California, Los Angeles, CA 90095, USA
3 DaVita, Inc., El Segundo, CA 90245, USA
4 DaVita Clinical Research, Minneapolis, MN, USA
5 School of Public Health, University of California, Los Angeles, CA 90095, USA

* To whom correspondence should be addressed.
Kamyar Kalantar-Zadeh, E-mail: kamkal{at}ucla.edu



  Abstract

Background. Hypoalbuminaemia is a marker of malnutrition-inflammation complex syndrome (MICS) and a strong predictor of cardiovascular (CV) death in maintenance haemodialysis (MHD) patients. However, serum albumin may change over time. Hence, its time-varying associations with outcome may be different.

Methods. Associations between 3-month averaged serum albumin levels, measured in a single laboratory using bromocresol green, and CV mortality were studied longitudinally in a 2-year cohort of 58 058 MHD patients. Mortality predictability of fixed baseline and trimonthly-varying serum albumin concentrations were compared.

Results. Hazard ratios (HRs) of CV death strictly increased across decrements of baseline serum albumin, whereas the HR for time-varying serum albumin decrements below 3.8 g/dl did not differ. A drop in serum albumin in the first 6 months was associated with increasing all-cause and CV death risks in the subsequent 18 months, while a rise in serum albumin was a predictor of better survival independent of baseline serum albumin. The multivariate adjusted population-attributable fraction of death due to baseline serum albumin <3.8 g/dl was 19%.

Conclusions. Time-varying hypoalbuminaemia predicts all-cause and CV death differently from fixed measures of serum albumin in MHD patients. An increase in serum albumin over time is associated with better survival independent of baseline serum albumin or other MICS surrogates. If this association is causal, an intervention that could increase serum albumin >3.8 g/dl might reduce the number of MHD deaths in the USA by 10 000 annually. Nutritional interventions examining benefits of increasing serum albumin in MHD patients are urgently needed.

Keywords: albumin; cardiovascular death; haemodialysis; malnutrition-inflammation complex syndrome; population-attributable fraction; time-dependent Cox model.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
D. Miskulin, J. Bragg-Gresham, B. W. Gillespie, F. Tentori, R. L. Pisoni, H. Tighiouart, A. S. Levey, and F. K. Port
Key Comorbid Conditions that Are Predictive of Survival among Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1818 - 1826.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
C. P Kovesdy, S. M George, J. E Anderson, and K. Kalantar-Zadeh
Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease
Am. J. Clinical Nutrition, August 1, 2009; 90(2): 407 - 414.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Kalantar-Zadeh, D. L. Regidor, C. P. Kovesdy, D. Van Wyck, S. Bunnapradist, T. B. Horwich, and G. C. Fonarow
Fluid Retention Is Associated With Cardiovascular Mortality in Patients Undergoing Long-Term Hemodialysis
Circulation, February 10, 2009; 119(5): 671 - 679.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. Rambod, C. P Kovesdy, R. Bross, J. D Kopple, and K. Kalantar-Zadeh
Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis
Am. J. Clinical Nutrition, December 1, 2008; 88(6): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
C. S Shinaberger, S. Greenland, J. D Kopple, D. Van Wyck, R. Mehrotra, C. P Kovesdy, and K. Kalantar-Zadeh
Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?
Am. J. Clinical Nutrition, December 1, 2008; 88(6): 1511 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
J. D. Kopple, A. K. Cheung, J. S. Christiansen, C. B. Djurhuus, M. El Nahas, B. Feldt-Rasmussen, M. Lange, W. E. Mitch, C. Wanner, J. Wiedemann, et al.
OPPORTUNITYTM: A Randomized Clinical Trial of Growth Hormone on Outcome in Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1741 - 1751.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. Mafra, F. Guebre-Egziabher, and D. Fouque
Body mass index, muscle and fat in chronic kidney disease: questions about survival
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2461 - 2466.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
S. Badiou, J.-P. Cristol, I. Jaussent, N. Terrier, M. Morena, F. Maurice, H. Leray-Moragues, J.-P. Rivory, L. Chalabi, C. Delcourt, et al.
Fine-Tuning of the Prediction of Mortality in Hemodialysis Patients by Use of Cytokine Proteomic Determination
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 423 - 430.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
N. J.M. Cano, D. Fouque, H. Roth, M. Aparicio, R. Azar, B. Canaud, P. Chauveau, C. Combe, M. Laville, X. M. Leverve, et al.
Intradialytic Parenteral Nutrition Does Not Improve Survival in Malnourished Hemodialysis Patients: A 2-Year Multicenter, Prospective, Randomized Study
J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2583 - 2591.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. Feldt-Rasmussen, M. Lange, W. Sulowicz, U. Gafter, K. N. Lai, J. Wiedemann, J. S. Christiansen, M. El Nahas, and and the Adult Patients in Chronic Dialysis (APCD)
Growth Hormone Treatment during Hemodialysis in a Randomized Trial Improves Nutrition, Quality of Life, and Cardiovascular Risk
J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2161 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. Kalantar-Zadeh, R. D. Kilpatrick, C. J. McAllister, L. G. Miller, E. S. Daar, D. W. Gjertson, J. D. Kopple, and S. Greenland
Hepatitis C Virus and Death Risk in Hemodialysis Patients
J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1584 - 1593.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
D. Schmidt and A. Salahudeen
The Obesity-Survival Paradox in Hemodialysis Patients: Why Do Overweight Hemodialysis Patients Live Longer?
Nutr Clin Pract, February 1, 2007; 22(1): 11 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Joki, H. Hase, Y. Tanaka, Y. Takahashi, T. Saijyo, H. Ishikawa, Y. Inishi, Y. Imamura, H. Hara, T. Tsunoda, et al.
Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients
Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1633 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
D. L. Regidor, J. D. Kopple, C. P. Kovesdy, R. D. Kilpatrick, C. J. McAllister, J. Aronovitz, S. Greenland, and K. Kalantar-Zadeh
Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients
J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1181 - 1191.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.